ClinicalTrials.gg
CompletedNCT02977416OSE-JIAUpdated Nov 10, 2026

Oxidation Rates of the Different Substrates During Exercise in Children and Adolescents With Juvenile Idiopathic Arthritis. Case-control Study and Cases Treated / Cases Not Treated With Anti-TNFα

An interventional study of anti-TNFα in Juvenile Idiopathic Arthritis, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 8 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other

How we know

Updated Nov 10, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.

Planned enrollment
23rd of 50
76 · median 61
Started
2017
with 4 others
No phase
13 of 71
4 open now
Registered
32nd of 71
by date
Lead sponsor
6 of 71
University Hospital, Clermont-Ferrand

Among the 71 studies in Arthritis, Juvenile with a site in France, this one is the 23rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2017, is one of 13 with no phase, and was the 32nd registered.

Arthritis, Juvenile

367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Arthritis, Juvenile with a site in France, or all of them as a file.
02

Study summary

During exercise, energy comes mainly from carbohydrates and lipids. The relative contribution of lipids and glucose as energy substrates to exercise depends on the parameters of the exercise (duration, intensity and level of training) and the physiological conditions of the subject.

Inflammatory diseases such as juvenile idiopathic arthritis (JIA) are treated, for the most severe forms, by biotherapies. These treatments target certain pro-inflammatory cytokines including TNFα. In adults with rheumatoid arthritis several studies have shown that treatment with anti-TNFα increases insulin sensitivity. There is no data on the oxidation of energy substrates during exercise in children and adolescents with AJI, nor on the impact of anti-TNFα treatments on the oxidation of energetic substrates in children.

Investigators hypothesize that, compared to healthy children, children with JIA should exhibit altered oxidation of energy substrates at rest and submaximal physical exercise due to physical deconditioning and inflammation. In addition, those treated with anti-TNFα should have an oxidation profile of energy substrates at exercise different from that of patients not treated with anti-TNFα. Investigators also hypothesize that anti-TNFα treatments modify the contribution of energy chains (aerobic, anaerobic and anaerobic alactic) during the exercise.

Read the detailed description

Annual evaluation by Lipoxmax test and Wingate anaerobic test (WAnT) during 3 years or until the transition from pediatric to adult care.

For healthy volunteer, only one lipaxmax and Wingate test.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Keywords

  • Juvenile idiopathic arthritis
  • fat oxidation
  • exercise
04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with juvenile idiopathic arthritis

Exclusion criteria

Exclusion Criteria:

  • active infection
  • > 25
  • Systemic within last 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    patients treated withTNF blockade

    22 patients treated with TNF blockade

    Other: anti-TNFα

  • Experimental
    patients without TNF blockade

    22 patients without TNF blockade

    Other: anti-TNFα

  • Experimental
    healthy subjects

    22 matched healthy subjects by pubertal stage and sex

    Other: anti-TNFα

Interventions

  • Otheranti-TNFα
06

What researchers measure

Primary outcomes

  1. Percentage variation of the maximal fat oxidative rate during an exercise between JIA and healthy children. Timing:

    Time frame: at day 1 (first test)

Secondary outcomes

  1. Percentage variation of substrates oxidative crossing point during an exercise.

    Time frame: at day 1

  2. Description of the contribution of energy systems during supra-maximal physical exercise

    Description of the contribution of energy systems during supra-maximal physical exercise in patients with JIA according to JIA subtype, treatments, age, pubertal status, disease status

    Time frame: at day 1 (first test)

07

Study locations

1 site
  • CHU Clermon-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Rochette E, Bourdier P, Pereira B, Dore E, Birat A, Ratel S, Echaubard S, Duche P, Merlin E. TNF blockade contributes to restore lipid oxidation during exercise in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2019 Jul 22;17(1):47. doi: 10.1186/s12969-019-0354-1. PubMed 31331342 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jun 2019, 29 months.

Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's 29 months is above that.

Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Nov 2016 → Jan 2017, primary completion May 2020 → Jun 2019 and completion Sep 2020 → Mar 2021.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2016
First posted
Nov 30, 2016
StartActual
Jan 17, 2017was Nov 2016
Primary completionActual
Jun 22, 2019was May 2020
CompletionActual
Mar 22, 2021was Sep 2020
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 10, 2026
Start date
Nov 2016→Jan 17, 2017 (actual)
Nov 10, 2026
Primary completion
May 2020→Jun 22, 2019 (actual)
Nov 10, 2026
Study completion
Sep 2020→Mar 22, 2021 (actual)
Nov 10, 2026
Enrollment
66→76
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Status unknown→Completed
    Start date Nov 2016→Jan 17, 2017 (now actual)
    Primary completion May 2020→Jun 22, 2019 (now actual)
    Study completion Sep 2020→Mar 22, 2021 (now actual)
    Enrollment 66→76
    + 4 other changes: design details, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02977416
Responsible party
Sponsor
First posted
Nov 30, 2016
Start date
Jan 17, 2017
Primary completion
Jun 22, 2019
Completion
Mar 22, 2021
Last update
Nov 10, 2026

Study contacts

Etienne MERLIN
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion